RxDoctor Payments Data

Christen Crisostomo, MD

Family Medicine · Suffolk, VANPI 1891985172

Payments from drug & device makers

$15,193in general payments, 2019–2025

Across 951 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$1K
  • Pfizer$1K
  • Lilly USA, LLC$965
  • GSK$924
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$15,181100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,193 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$167,546
Medicare patients
400
Services billed
2,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$89,678
JardianceEmpagliflozin71$88,732
EliquisApixaban44$54,991
FarxigaDapagliflozin Propanediol71$54,163
JanuviaSitagliptin Phosphate35$42,158
MounjaroTirzepatide25$25,361
XareltoRivaroxaban14$19,050
MyrbetriqMirabegron16$12,603
Spiriva RespimatTiotropium Bromide13$10,745
Rosuvastatin Calcium268$5,207
Atorvastatin Calcium362$3,860
Celecoxib62$3,261
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$3,069
SymbicortBudesonide/Formoterol Fumarate11$2,509
Epinephrine14$2,224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$815$99,47784 claims
Novo NordiskOzempic$1,632$89,67890 claims
AstraZenecaFarxiga, Symbicort$1,450$56,67282 claims
PfizerEliquis$1,249$54,99144 claims
MerckJanuvia$579$42,15835 claims
Lilly USA, LLCMounjaro$965$25,36125 claims
Johnson & JohnsonXarelto$397$19,05014 claims
Astellas Pharma US IncMyrbetriq$296$12,60316 claims
AbbVieSynthroid$1,583$1,28618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Suffolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →